Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia

Leukemia

Volumn 28, Issue 7, 2014, Pages 1545-1548

  Matsuda, K ^a   Nakazawa, Y ^b   Iwashita, C ^a   Kurata, T ^b   Hirabayashi, K ^b   Saito, S ^b   Tanaka, M ^b   Yoshikawa, K ^b   Yanagisawa, R ^b   Sakashita, K ^b   Sasaki, S ^c   Honda, T ^a   Koike, K ^b  

^a SHINSHU UNIVERSITY HOSPITAL   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; HEMOGLOBIN; HEMOGLOBIN F; JANUS KINASE 3; K RAS PROTEIN; MERCAPTOPURINE; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ADULT; CASE REPORT; CHILD; FEMALE; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LETTER; LEUKOCYTE; MALE; MYELOID PROGENITOR CELL; ONCOGENE N RAS; PRESCHOOL CHILD; PRIORITY JOURNAL; THROMBOCYTE; YOUNG ADULT;

6-MERCAPTOPURINE; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MALE; MUTATION; NEOPLASTIC STEM CELLS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84904063832     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.58     Document Type: Letter

References (14)

1. Koike K, Matsuda K. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Br J Haematol 2008 141 567-575.
2. Loh ML. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol 2011 152 677-687.
3. Sakaguchi H, Okuno Y, Muramatsu H, Yoshida K, Shiraishi Y, Takahashi M et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet 2013 45 937-941.
4. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013 45 18-24.
5. Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013 27 1401-1403.
6. Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013 45 942-946.
7. Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia 2013 27 1852-1860.
8. Thol F, Suchanek KJ, Koenecke C, Stadler M, Platzbecker U, Thiede C et al. SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia 2013 27 2072-2075.
9. Shiba N, Ohki K, Park MJ, Sotomatsu M, Kudo K, Ito E et al. SETBP1 mutations in juvenile myelomonocytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia. Br J Haematol 2013 164 156-159.
10. Matsuda K, Matsuzaki S, Miki J, Hidaka E, Yanagisawa R, Nakazawa Y et al. Chromosomal change during 6-mercaptopurine (6-MP) therapy in juvenile myelomonocytic leukemia the growth of a 6-MP-refractory clone that already exists at onset. Leukemia 2006 20 485-490.
11. Matsuda K, Nakazawa Y, Sakashita K, Shiohara M, Yamauchi K, Koike K. Acquisition of loss of the wild-type NRAS locus with aggressive disease progression in a patient with juvenile myelomonocytic leukemia and a heterozygous NRAS mutation. Haematologica 2007 92 1576-1578.
12. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003 34 148-150.
13. Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergsträsser E, Emanuel PD et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 2005 106 2183-2185.
14. Matsuda K, Sakashita K, Taira C, Tanaka-Yanagisawa M, Yanagisawa R, Shiohara M et al. Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia. Br J Haematol 2010 148 593-599.